IgA Nephropathy Market Size in the 7MMwas ~USD 700 Million in 2024 and it is expected to grow at a significant CAGR by 2034, according to DelveInsight

The IgA Nephropathy Market Size (7MM) was valued at ~USD 700 Million in 2024 and is projected to grow at a CAGR of 30.50% during the study period (2020–2034). DelveInsight’s Comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the IgA Nephropathy Market Landscape. By analyzing historical data, current IgA Nephropathy Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The IgA Nephropathy Market is increasingly guided by biomarker-driven strategies. IgA Nephropathy is a chronic kidney disease in which the antibody immunoglobulin A (IgA) builds up in the kidneys, causing inflammation and damage to the tiny filtering units known as glomeruli. This buildup interferes with the kidneys’ ability to properly filter waste and excess fluids from the blood. The condition often develops gradually and may present with symptoms such as blood in the urine (hematuria), protein in the urine (proteinuria), swelling in the hands and feet, and high blood pressure. In some patients, the disease progresses slowly, while in others it can lead to worsening kidney function and eventually chronic kidney disease or kidney failure over time.

DelveInsight’s report, “IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the IgA Nephropathy Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines IgA Nephropathy Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the IgA Nephropathy Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ IgA Nephropathy Market Forecast

Key Takeaways from IgA Nephropathy Market Report

• DelveInsight estimates that there were approximately 415 thousand prevalent cases of IgAN across the 7MM in 2024. These diagnosed prevalent cases are projected to rise by 2034 at a CAGR of 0.6%.
• In 2024, the US accounted for around 133 thousand diagnosed prevalent cases of IgAN, expected to increase by 2034.
• Between EU4 and the UK, Germany had the highest number of diagnosed prevalent cases of IgAN in 2024, with approximately 30 thousand cases, while Spain had the lowest, with around 5 thousand cases.
• In 2024, Japan recorded the highest number of diagnosed prevalent cases of IgAN among the 7MM, nearly 175 thousand, which is expected to rise by 2034.
• In terms of gender-specific diagnosed prevalent cases of IgAN, France had approximately 16 thousand male and 8 thousand female cases in 2024, with these numbers expected to rise by 2034.
• Regarding age-specific diagnosed prevalent cases of IgAN, the UK reported nearly 2 thousand, 11 thousand, 11 thousand, and 3 thousand cases in the <18 years, 18–45 years, 46–65 years, and >65 age groups in 2024. These numbers are expected to grow by 2034.
• The leading IgA Nephropathy Companies such as Novartis, F. Hoffmann-La Roche, Ionis Pharmaceuticals, AstraZeneca (Alexion Pharmaceuticals), Vertex Pharmaceuticals, Otsuka Pharmaceutical, Biogen, Arrowhead Pharmaceuticals, NovelMed, Q32 Bio, Walden Biosciences, Takeda Pharmaceutical, Vera Therapeutics and others.
• Promising IgA Nephropathy Therapies such as LNP023, Blisibimod, HR19042 Capsules, Nefecon, Telitacicept, Intravenous Rituximab, HRS-5965, BION-1301, Atrasentan, and others.

IgA Nephropathy Overview

IgA Nephropathy is a progressive kidney condition caused by the abnormal accumulation of the antibody immunoglobulin A (IgA) in the glomeruli, the small filtering structures of the kidneys. This buildup triggers inflammation that can impair the kidneys’ ability to filter blood efficiently. The disease may initially present with symptoms such as blood in the urine, foamy urine due to excess protein, swelling in the legs or ankles, and elevated blood pressure. In many individuals, IgA nephropathy progresses slowly, but in some cases it can lead to worsening kidney damage and eventually chronic kidney failure.

Get a Free sample for the IgA Nephropathy Market Report @ https://www.delveinsight.com/report-store/iga-nephropathy-us-market

Key Factors in IgA Nephropathy Therapeutics Market

• Rising Prevalence of Kidney Disorders: The increasing incidence of chronic kidney diseases, including IgA Nephropathy, is contributing to a growing patient population requiring effective therapeutic interventions.
• Advancements in Targeted Therapies: Ongoing research into novel targeted treatments, including immunomodulatory therapies and complement inhibitors, is expanding the treatment landscape and improving disease management.
• Improved Diagnostic Capabilities: Advancements in diagnostic techniques and increased screening for kidney diseases are enabling earlier detection of IgA Nephropathy, supporting timely treatment and better patient outcomes.
• Growing Investment in Research and Development: Pharmaceutical companies and research institutions are actively investing in the development of innovative therapies aimed at addressing the underlying causes of the disease.
• Expansion of the Clinical Pipeline: A robust pipeline of investigational drugs undergoing clinical trials is expected to introduce new treatment options, driving market growth in the coming years.
• Increasing Healthcare Awareness: Rising awareness among healthcare professionals and patients regarding kidney health and rare renal disorders is encouraging early diagnosis and improved treatment adoption.

IgA Nephropathy Epidemiology Segmentation in the 7MM

The IgA Nephropathy Market Report proffers epidemiological analysis for the study period 2022-2034 in the 7MM segmented into-

• Total Diagnosed Prevalent Cases of IgAN
• Gender-specific Diagnosed Prevalent Cases of IgAN
• Age-specific Diagnosed Prevalent Cases of IgAN

Download the report to understand which factors are driving IgA Nephropathy Epidemiology trends @ IgA Nephropathy Epidemiology Forecast

Recent Development in the IgA Nephropathy Treatment Landscape

• In March 2026, Biogen announced a phase 3 study is to evaluate the efficacy of felzartamab compared to placebo on proteinuria in participants with Immunoglobulin A nephropathy (IgAN). The main secondary objective of the study is to evaluate the efficacy of felzartamab compared to placebo on kidney functions in participants with IgAN. The additional secondary objectives are to evaluate the efficacy of felzartamab compared to placebo on additional clinical endpoints and to assess the pharmacokinetics (PK) and immunogenicity of felzartamab.
• In March 2026- Takeda initiated a study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find out if and how well mezagitamab continues to maintain kidney function over the long term compared to placebo.
• In March 2026- ADARx Pharmaceuticals Inc. conducted a Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.

IgA Nephropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential IgA Nephropathy drugs recently launched in the IgA Nephropathy market or expected to get launched during the study period. The analysis covers IgA Nephropathy Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the IgA Nephropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

IgA Nephropathy Therapies and Companies

• LNP023: Novartis Pharmaceuticals
• Blisibimod: Anthera Pharmaceuticals
• HR19042 Capsules: Jiangsu HengRui Medicine Co., Ltd.
• Nefecon: Calliditas Therapeutics AB
• Telitacicept: RemeGen Co. Ltd.

To know more about IgA Nephropathy Companies working in the treatment market, visit @ IgA Nephropathy Clinical Trials and Therapeutic Assessment

IgA Nephropathy Market Drivers

• Rising Prevalence of Kidney Diseases: The increasing global burden of chronic kidney diseases is contributing to a growing number of diagnosed cases of IgA nephropathy, which is driving demand for effective treatment options.
• Growing Awareness and Early Diagnosis: Improved awareness among healthcare professionals and patients, along with advancements in diagnostic technologies, is enabling earlier detection of IgA nephropathy, supporting greater treatment adoption.
• Advancements in Targeted Therapies: The development of novel targeted therapies, including complement inhibitors and immunomodulatory drugs, is expanding treatment possibilities and driving innovation in the IgA nephropathy therapeutics market.
• Robust Drug Development Pipeline: Pharmaceutical companies are actively investing in research and development to introduce new therapies aimed at slowing disease progression and improving patient outcomes.
• Increasing Healthcare Expenditure: Rising healthcare spending in developed and emerging markets is improving access to advanced treatment options and supporting the adoption of innovative therapies.
• Supportive Regulatory Initiatives: Regulatory agencies are increasingly encouraging the development of treatments for rare kidney disorders through incentives such as orphan drug designations and accelerated approval pathways.
• Growing Focus on Precision Medicine: Advances in biomarker research and personalized treatment approaches are helping clinicians tailor therapies based on individual patient characteristics, enhancing treatment effectiveness.

IgA Nephropathy Market Barriers

• Delayed and Asymptomatic Diagnosis: IgA Nephropathy often progresses silently in its early stages, with many patients showing mild or no symptoms. This leads to delayed diagnosis and treatment initiation, limiting timely therapeutic intervention.
• Limited Curative Treatment Options: Most currently available therapies focus on managing symptoms, controlling blood pressure, and slowing disease progression rather than providing a definitive cure, which restricts the overall effectiveness of treatment strategies.
• High Cost of Emerging Therapies: Novel targeted therapies and advanced treatment options for IgA Nephropathy can be expensive, creating affordability issues for patients and healthcare systems, particularly in developing regions.
• Adverse Effects of Long-Term Treatments: Many existing treatment approaches, including corticosteroids and immunosuppressive drugs, may cause significant side effects, affecting patient adherence and long-term treatment use.
• Complex Disease Pathogenesis: The exact mechanisms underlying IgA Nephropathy are not fully understood, which creates challenges in developing highly effective targeted therapies.
• Challenges in Clinical Trial Enrollment: Recruiting sufficient participants for clinical studies can be difficult due to strict eligibility criteria and the slow progression of the disease, potentially delaying drug development.
• Limited Awareness and Screening Programs: In many regions, insufficient awareness and lack of routine screening programs lead to underdiagnosis and delayed treatment, restricting market growth.
• Variability in Disease Progression: The disease progresses differently among patients, making it difficult to standardize treatment approaches and evaluate therapeutic outcomes in clinical trials.

Scope of the IgA Nephropathy Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• IgA Nephropathy Companies- Novartis, F. Hoffmann-La Roche, Ionis Pharmaceuticals, AstraZeneca (Alexion Pharmaceuticals), Vertex Pharmaceuticals, Otsuka Pharmaceutical, Biogen, Arrowhead Pharmaceuticals, NovelMed, Q32 Bio, Walden Biosciences, Takeda Pharmaceutical, Vera Therapeutics, and others.
• IgA Nephropathy Therapies- LNP023, Blisibimod, HR19042 Capsules, Nefecon, Telitacicept, Intravenous Rituximab, HRS-5965, BION-1301, Atrasentan, and others.
• IgA Nephropathy Therapeutic Assessment: IgA Nephropathy current marketed and emerging therapies
• IgA Nephropathy Market Dynamics: IgA Nephropathy market drivers and IgA Nephropathy market barriers
• IgA Nephropathy Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• IgA Nephropathy Unmet Needs, KOL’s views, Analyst’s views, IgA Nephropathy Market Access and Reimbursement

Discover more about therapies set to grab the major IgA Nephropathy Market Share @ IgA Nephropathy Treatment Market

Table of Contents

1. Key Insights

2. IgA Nephropathy Market Report Introduction

3. IgA Nephropathy Executive Summary

4. IgA Nephropathy Key Events

5. IgA Nephropathy Epidemiology and Market Forecast Methodology

6. IgA Nephropathy Market Overview at a Glance

7. IgA Nephropathy Disease Background and Overview

8. IgA Nephropathy Epidemiology and Patient Population

9. IgA Nephropathy Patient Journey

10. IgA Nephropathy Marketed Drugs

11. IgA Nephropathy Emerging Drugs

12. IgA Nephropathy: 7MM Analysis

13. IgA Nephropathy Unmet Needs

14. IgA Nephropathy SWOT Analysis

15. IgA Nephropathy KOL Views

16. IgA Nephropathy Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.